SEC Form 4	
------------	--

 $\square$ 

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

FORM 4

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* List Alan			2. Issuer Name and Ticker or Trading Symbol <u>PRECISION BIOSCIENCES INC</u> [DTIL]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					Director	10% Owner			
		6	Dete of Ferlinet Transportion (Manth/Dev/Marr)	<b>-</b> X	Officer (give title below)	Other (specify below)			
(Last) C/O PRECISI	(First)	(Middle) NCES, INC.	3. Date of Earliest Transaction (Month/Day/Year) 03/03/2023		Chief Medica	l Officer			
302 EAST PE	TTIGREW ST	F. SUITE A-100							
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	ndividual or Joint/Group Filing (Check Applicable e)				
(Street) DURHAM				X	Form filed by One Reporting Person				
	NC	27701			Form filed by More the Person	an One Reporting			
(City)	(State)	(Zip)							
		Table I - Non-De	erivative Securities Acquired, Disposed of, or Bene	ficially	Owned				

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities A Disposed Of ( 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	03/03/2023		М		29,453 <sup>(1)</sup>	Α	(2)	47,713	D	
Common Stock	03/06/2023		<b>S</b> <sup>(3)</sup>		9,473	D	\$1.07	38,240	D	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(2)	03/03/2023		М		29,453		(4)	(4)	Common Stock	29,453	\$0.00	58,890	D	

### Explanation of Responses:

1. Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 3, 2023.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

4. On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

#### **Remarks:**

/s/ Dario Scimeca, Attorney-in-03/07/2023 Fact for Alan List

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.